Biologica in patients with Crohn's disease in Germany
- Conditions
- K50Crohn disease [regional enteritis]
- Registration Number
- DRKS00009234
- Lead Sponsor
- CED Service GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 1550
Inclusion Criteria
1. Crohn's disease patients (age at inclusion: 18-80 years ) with a new biologics therapy with Adalimumab, Infliximab, Certolizumab, Golimumab or Vedolizumab.
2. Crohn's disease patients (age at inclusion: 18-80 years ) with an early disease history (initial diagnosis < 3 years).
Exclusion Criteria
Age under 18 years and over 80 years
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method